Lucent Diagnostics, a brand of Quanterix, has partnered with Tempus AI to integrate blood-based Alzheimer’s biomarker testing directly into routine clinical workflows, aiming to simplify and accelerate the path to diagnosis. Through the collaboration, the LucentAD Complete multi-biomarker blood test will be available for neurologists to order within the Tempus clinical platform, enabling a more streamlined and less invasive approach to identifying patients who may be eligible for newly approved Alzheimer’s therapies. The initiative addresses a significant gap in care, as only a small fraction of the approximately 7 million Americans living with Alzheimer’s are currently evaluated for treatment eligibility.
A key component of the partnership is Tempus Next, an AI-enabled care pathway platform designed to surface “care gaps” by identifying patients who meet guideline-based criteria for testing but have not yet been assessed. By analyzing real-world clinical data and integrating with electronic health records, the platform functions as a decision-support layer within existing workflows, allowing neurologists to act on these insights at the point of care. This reduces the friction typically associated with adopting new diagnostic tools and helps ensure that more patients are evaluated earlier in the disease progression, when interventions may be most effective.
The diagnostic capability itself is powered by Quanterix’s Simoa technology, which is designed for ultra-sensitive detection of biomarkers associated with amyloid-positive Alzheimer’s disease. Unlike traditional diagnostic approaches such as PET scans or spinal taps, which can be costly or invasive, this blood-based test offers a more accessible alternative that can be more easily incorporated into routine practice. By enabling earlier and more accurate identification of patients, the technology supports a shift toward more proactive and personalized care.
Overall, the collaboration reflects a broader movement to bring precision diagnostics out of specialized settings and into everyday clinical use. By combining AI-driven patient identification with high-sensitivity biomarker testing, Lucent and Tempus aim to close longstanding gaps between symptom onset, diagnosis and treatment, ultimately improving access to care and outcomes for patients with Alzheimer’s.
Click here to read the original news story.
